News
RNZ on MSN12d
Ozempic And Wegovy: The Pros And Cons, ExplainedGetting into the exercise habit was also important since one day, most people on Ozempic or Wegovy will stop taking it - putting themselves at risk of putting the weight back on if they were not ...
This story has been corrected as an earlier version said Wegovy AND Ozempic had been made available on prescription for weight loss in New Zealand but it is only Wegovy. Earlier this week, semaglutide ...
The weight loss and diabetes drug, which is only available on prescription, should be on pharmacy shelves within days ending ...
Speaking in Auckland this morning, Prime Minister Christopher Luxon said the New Zealand Institute for Advanced Technology will be based focus on turning technologies like AI and quantum computing ...
Biocon aims to launch generic copies of the blockbuster weight-loss drug Wegovy in India and Canada within the next two years ...
Biopharmaceutical company Biocon is planning to submit a request for approval of generic copies of the blockbuster ...
A Wellington man is stoked to finally get his hands back on the weight loss drug he said changed his life. Wegovy was ...
Biocon aims to launch generic copies of the blockbuster weight-loss drug Wegovy in India and Canada within the next two years, a top executive told Reuters ...
Biocon share price gained 2.5 per cent after reports suggested that the company is planning to file for generic versions of Novo Nordisk A/S's Ozempic and Wegovy ...
13d
Atlanta Black Star on MSN‘Looks So Much Better Now’: Russell Crowe Shows Off His Drastic Weight Loss at Award Show with Fiancée Britney TheriotGladiator” actor Russell Crowe, 61, is flaunting his new slimmer physique in public. Photos of Crowe at the Mediterrane Film ...
Biocon Ltd. plans to file for regulatory approvals of generic versions of Novo Nordisk A/S’s Ozempic and Wegovy in key markets as it races to be among the first few to reap a windfall after patents on ...
Biocon is set to launch generic versions of Wegovy in India and Canada, aiming for market entry by late 2026 or early 2027.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results